secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-05-16T23:59:59+00:00
Accession:  0001193125-25-121824
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics raises ~$16M in registered direct offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Gross proceeds ~$16M from 834,237 shares at $6.61/share and pre-funded warrants for 1,587,108 shares at $6.6099.
- Pre-funded warrants have exercise price $0.0001/share, exercisable immediately, no expiration.
- Net proceeds to fund BLA approval activities for tab-cel and for working capital.
- Underwriting agreement with TD Securities; offering expected to close May 16, 2025.
- 30-day lock-up on issuance and sale of company securities post-closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525121824/0001193125-25-121824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525121824/d45771d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-121824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer